STENYSEOrthopedic, Prosthetic & Surgical Appliances & SuppliesFiscal year ends March 31
STERIS plc
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$221.97−0.69 (-0.31%)
Close on Oct 19, 2026
- Market cap
- $21.73B
- P/E (TTM)
- 27.1
- Dividend yield
- 1.11%
STERIS plc revenue by segment
By business segment
| Revenue | Q1 27 | Q4 26 | Q3 26 | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Healthcare | $1.05B | $1.14B | $1.06B | $1.03B | $974.70M | $1.06B | $976.00M | $944.30M | $901.20M | – | – | – | 70.2% | +7.6% |
| Applied Sterilization Technologies | $297.60M | $289.20M | $286.60M | $281.50M | $281.20M | $273.90M | $258.10M | $256.70M | $249.80M | $250.92M | $234.93M | $235.05M | 19.9% | +5.8% |
| Life Sciences: | $146.70M | – | $145.80M | $145.00M | $135.20M | – | $136.40M | $127.90M | – | – | – | – | 9.8% | +8.5% |
| Life Sciences | – | – | – | – | $135.20M | $149.50M | $136.38M | $127.95M | $128.50M | $160.63M | $146.57M | $133.10M | – | – |
| Healthcare [Member] [Member] | – | – | – | – | – | – | $976.04M | $944.23M | $901.22M | – | $916.23M | $870.06M | – | – |
| Dental | – | – | – | – | – | – | – | – | – | – | $97.92M | $104.16M | – | – |
| Healthcare | – | – | – | $1.03B | $974.70M | – | – | $944.20M | $901.20M | – | – | – | – | – |
| Operating income | Q1 27 | Q4 26 | Q3 26 | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Healthcare | – | – | $258.10M | – | – | – | $246.90M | – | – | – | – | – | – |
| Applied Sterilization Technologies | – | – | $129.20M | $127.60M | – | – | $115.80M | $109.90M | $117.71M | – | $105.16M | $110.78M | – |
| Life Sciences: | – | – | $61.80M | $59.90M | – | – | $58.10M | $53.70M | – | – | – | – | – |
| Life Sciences | – | – | – | – | – | – | $58.13M | $53.70M | $52.58M | – | $56.74M | $50.28M | – |
| Healthcare [Member] [Member] | – | – | – | – | – | – | $246.92M | $228.01M | $216.89M | – | $223.90M | $204.05M | – |
| Dental | – | – | – | – | – | – | – | – | – | – | $18.29M | $24.52M | – |
| Segment operating income | – | – | $343.10M | $337.10M | – | – | $320.00M | $294.50M | $285.44M | – | $304.23M | $278.10M | – |
| Corporate | – | – | -$106.00M | -$109.90M | – | – | -$100.80M | -$97.10M | -$101.75M | – | -$81.56M | -$87.02M | – |
| Healthcare | – | – | – | $259.50M | – | – | – | $228.00M | – | – | – | – | – |
By product or service
| Revenue | Q1 27 | Q4 26 | Q3 26 | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Service [Member] | $755.50M | $743.10M | $717.30M | $714.90M | $700.60M | $679.50M | $652.20M | $633.00M | $623.20M | $633.10M | $590.89M | $580.02M | 50.6% | +7.8% |
| Product [Member] | $737.20M | $845.30M | $778.90M | $745.40M | $690.50M | $801.10M | $718.30M | $695.90M | $656.30M | $786.28M | $706.84M | $658.18M | 49.4% | +6.8% |
By region
| Revenue | Q1 27 | Q4 26 | Q3 26 | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $1.09B | $1.15B | $1.09B | $1.08B | $1.03B | $1.08B | $1.00B | $979.50M | $946.90M | $1.04B | $949.96M | $909.65M | 73.1% | +6.3% |
| Other locations | $373.20M | – | $382.30M | – | $342.90M | – | $343.90M | – | – | – | – | – | 25.0% | +8.8% |
| Ireland | $29.00M | $31.90M | $26.70M | $27.30M | $22.50M | $38.20M | $24.10M | $22.80M | $22.20M | $22.66M | $19.60M | $20.40M | 1.9% | +28.9% |
| Other foreign locations | – | – | – | $357.80M | $342.90M | $363.73M | $343.87M | $326.60M | $310.40M | $360.72M | $328.17M | $308.15M | – | – |
From the segment and revenue-disaggregation notes of Steris's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.